Intent to Use. Neither Seller nor any of its Affiliates has submitted to the FDA a notification of intent to use the Priority Review Voucher, as described in 21 U.S.C. 360bbb-4a(b)(3).
Appears in 1 contract
Intent to Use. Neither Seller nor any of its Affiliates has filed or submitted to the FDA a notification of intent to use the Priority Review Voucher, as described in 21 U.S.C. 360bbb-4a(b)(3USC 360ff(b)(4)(A).
Appears in 1 contract
Samples: Asset Purchase Agreement (Sarepta Therapeutics, Inc.)
Intent to Use. Neither Seller nor any of its Affiliates has filed or submitted to the FDA a notification of intent to use the Priority Review Voucher, as described in 21 U.S.C. 360bbb-4a(b)(3USC 360ff(b)(4)(B).
Appears in 1 contract
Samples: Asset Purchase Agreement (Rhythm Pharmaceuticals, Inc.)
Intent to Use. Neither Seller nor Asklepion, nor any of its Affiliates their respective Affiliates, has filed or submitted to the FDA a notification of intent to use the Priority Review Voucher, as described in 21 U.S.C. 360bbb-4a(b)(3USC 360ff(b)(4)(A).
Appears in 1 contract